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L eukemia is among the most common malignanciesassociated with hospital admissions for acute kid-
ney injury (AKI).1,2 AKI develops in up to one-third of
patients affected by hematologic malignancy, particu-
larly in older patients with prior chronic kidney dis-
ease (CKD),3 and has been shown to have an adverse
effect on long-term prognosis in this patient popula-
tion.4 Intravascular volume depletion, tumor lysis syn-
drome, and drug-induced acute tubular injury are
among the most common causes of leukemia-
associated AKI.4,5 Radiologic studies may be useful to
exclude obstructive uropathy secondary to retroperito-
neal lymphadenopathy or tumorous masses. Direct
inﬁltration of the renal parenchyma by leukemic cells,
although a common ﬁnding at autopsy,5 is only
rarely associated with the development of symptomatic
AKI.4 Rare cases of AKI secondary to intravascular
leukostasis have also been described, particularly in
patients with white blood cell counts greater than
100,000/mm3.6 Lysozyme-induced nephropathy (LyN)
is a rare and underrecognized complication of chronic
myelomonocytic leukemia (CMML) and other forms of
monocytic leukemia in which lysozyme, a small
cationic protein, is released into the circulation, ﬁltered
by the glomerulus and reabsorbed by the proximal tu-
bule, causing toxic tubular injury.7
CASE PRESENTATION
Clinical History and Initial Laboratory Data
A 69-year-old white man with a history of CKD
(baseline serum creatinine, 2.0 mg/dl; estimated
glomerular ﬁltration rate, 35 ml/min/1.73 m2) and well-
controlled HIV infection (CD4 count, 500 cells/mm3;
viral load, <20 copies/ml) presented to the emergency
department after 10 days of watery diarrhea. Two
months prior, he had been diagnosed with CMML, buthad not commenced treatment. Maintenance antiretro-
viral therapy included darunavir, emtricitibine, and
ritonavir. Physical examination ﬁndings were notable
for a blood pressure of 119/63 mm Hg, splenomegaly,
and the absence of edema.
Initial laboratory evaluation (Table 1) revealed
markedly elevated serum creatinine (10.9 mg/dl; esti-
mated glomerular ﬁltration rate, 5 ml/min/1.73 m2)
associated with oliguria. Complete blood count
revealed leukocytosis, anemia, and thrombocytopenia.
Urinalysis revealed 3þ protein by dipstick. Urine
protein:creatinine ratio was 6.7 g/g on a spot mea-
surement. Urinary microscopy, performed on a spec-
imen collected after Foley catheter insertion, showed 21
to 30 red blood cells and 31 to 40 white blood cells per
high-power ﬁeld, but no cellular casts or crystals.
Serologic workup results were negative (Table 1). The
patient showed no improvement in renal function with
volume resuscitation. In light of the additional labo-
ratory ﬁndings of hyperuricemia with hyper-
phosphatemia, hypocalcemia, and elevated lactate
dehydrogenase, the patient was started on dialysis and
allopurinol for suspected tumor lysis syndrome. A
kidney biopsy was performed on the 10th hospital day.
Kidney Biopsy Results
The sampling for light microscopy included 16
glomeruli, 2 of which were globally sclerotic. The
remaining 14 glomeruli appeared largely unremarkable,
and no lesions of focal segmental glomerulosclerosis
were identiﬁed. The predominant abnormalities
involved proximal tubular epithelial cells, which
exhibited widespread degenerative changes including
luminal ectasia, cytoplasmic simpliﬁcation and vacuo-
lization, irregular luminal proﬁles, loss of brush border,
enlarged nuclei with prominent nucleoli, and focal
apoptotic ﬁgures (Figure 1a). The proximal tubular
injury was accompanied by mild interstitial edema andKidney International Reports (2017) 2, 84–88
Table 1. Initial laboratory ﬁndings
Parameter Value (reference range)
SCr (mg/dl) 10.9 (0.6–1.2)
eGFR (ml/min/1.73 m2) 5 (>90)
Serum urea nitrogen (mg/dl) 72 (8–20)
Serum potassium (mmol/l) 4.4 (3.5–5.5)
Serum uric acid (mg/dl) 25 (3.8–8.0)
Serum phosphorus (mg/dl) 9.7 (2.4–4.1)
Serum calcium (mg/dl) 7.1 (8.5–10.2)
Serum albumin (g/dl) 2.5 (3.5–5.1)
LDH (IU/l) 1100 (140–280)
Hemoglobin (g/dl) 9 (12.0–16.0)
WBC count ( 103/ml) 67.4 (4.5–13.5)





Urine dipstick protein 3þ
Urine RBC (/hpf) 21–30 (none)a
Urine WBC (/hpf) 31–40 (0–2)a
Spot urine PCR (g/g) 6.7 (<0.3)
Urine culture No growth
C3 (mg/dl) 124 (88–165)




Hepatitis C antibody Neg (neg)
Anti-GBM antibody Neg (neg)
Hepatitis B core antigen Neg (neg)
Serum cryoglobulins Neg (neg)
SPEP No M-spike
ANA, antinuclear antibody; ANCA, antineutrophil cytoplasmic antibody; anti-GBM,
antiglomerular basement membrane; eGFR, estimated glomerular ﬁltration rate; hpf,
high-power ﬁeld; LDH, lactate dehydrogenase; MPO, myeloperoxidase; Neg, negative;
PCR, protein:creatinine ratio; RBC, red blood cell; SCr, serum creatinine; SPEP, serum
protein electrophoresis WBC, white blood cell.
Conversion factors for units: SCr in mg/dl to mmol/l, 88.4; SUN in mg/dl to
mmol/l, 0.357.
aResults obtained from Foley cathetercollected urine.
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cytes and monocytes. Many proximal tubular cells had
hypereosinophilic granular cytoplasm owing to the
presence of abundant intracytoplasmic, PAS-positive
granules (Figure 1b). Scattered larger rounded, eosin-
ophilic inclusions that were moderately periodic acid–
Schiff positive and nonargyrophilic with the Jones
methenamine silver stain were also seen (Figure 1h).
Immunohistochemical staining for lysozyme (Lysozyme
EP134; RabMAb, Rocklin, CA) revealed strong posi-
tivity in the distribution of the proximal tubular cell
cytoplasm (Figure 1c, d). No atypical casts or intra-
cytoplasmic crystalline-type inclusions were seen. Mild
tubular atrophy and interstitial ﬁbrosis involved 15%
of the cortex sampled.
Immunoﬂuorescence staining for IgG, IgM, IgA,
C3, C1, ﬁbrinogen, albumin, and kappa (k) and lambda
(l) light chains revealed no signiﬁcant positivity.
Immunoﬂuorescence staining for k and l light chainsKidney International Reports (2017) 2, 84–88repeated on pronase-digested parafﬁn tissue sections
again was negative, providing evidence against light
chain proximal tubuloapthy.
On ultrastructural evaluation, glomeruli exhibited no
signiﬁcant abnormalities. Speciﬁcally, there was only
10% foot process effacement, and no electron-dense
deposits were seen. Proximal tubules displayed diffuse
degenerative changes including loss of apical brush
border, cytoplasmic simpliﬁcation, dilatation of the
endoplasmic reticulum, and intraluminal cellular debris.
The most distinctive ﬁnding was abundant membrane-
bound cytoplasmic vacuoles containing clumped,
electron-dense, degenerating cellular organellar debris,
consistent with autophagolysosomes (Figure 1e, f). The
autophagolysosomes were diffusely distributed in
proximal tubular epithelia and in some instances formed
larger, membrane-bound aggregates that approached
the size of the nucleus (Figure 1g). No intracellular
crystals or dysmorphic mitochondria were identiﬁed.
Diagnosis
A diagnosis of lysozyme-induced nephropathy (LyN)
was made.
Clinical Follow-up
Additional testing revealed markedly elevated serum
lysozyme levels (101 mg/ml; nl range 2.7–9.4) and
lysozymuria (>11 mg/ml; nl <3), supporting a diag-
nosis of lysozyme-induced nephropathy. The patient
was started on chemotherapy with azacitidine, result-
ing in normalization of his white blood cell count.
Serum lysozyme levels remained elevated 4 months
after initiation of chemotherapy, but ultimately
decreased to within reference range. The patient
remained dialysis dependent from the time of kidney
biopsy, and expired 18 months later in the setting of
relapsing leukemia with blast crisis.
DISCUSSION
CMML is a rare, aggressive, malignant, hematopoietic
neoplasm that most commonly affects patients over the
age of 65 years and is characterized by peripheral blood
monocytosis with myelodysplastic features. Lysozyme,
also known as muramidase, is a lytic enzyme with
bactericidal properties that is synthesized by mono-
cytes and can be produced in large amounts by
neoplastic cells of monocyte lineage.7 Increased serum
and urine lysozyme levels (lysozymuria) were ﬁrst
described in patients with monocytic or myelomono-
cytic leukemia, including both acute and chronic
forms, in the late 1960s.8 Lysozyme-induced nephrop-
athy (LyN) is a rare and underrecognized cause of AKI
in a subset of these patients, particularly those with
CMML.3,7,985
Figure 1. A low-power view demonstrates widespread proximal tubular degenerative changes and interstitial edema. (a) A glomerulus appears
unremarkable (hematoxylin and eosin, original magniﬁcation 200). (b) At higher magniﬁcation, many proximal tubular cells are distended by
numerous small intracytoplasmic PASþ granules (arrow; periodic acid–Schiff, original magniﬁcation400). (c) Immunohistochemial staining for
lysozyme shows intense granular reactivity in the distribution of proximal tubular cell cytoplasm (immunoperoxidase, original magniﬁcation100).
(d) No signiﬁcant staining is seen in a paired negative control obtained from an allograft postreperfusion biopsy (immunoperoxidase, original
magniﬁcation 100). (e) On ultrastructural evaluation, proximal tubular cells contain abundant membrane-bound vacuoles (arrow; original
magniﬁcation8000). (f) On closer inspection, the vacuoles in proximal tubules contain clumped, degenerating organellar debris, consistent with
autophagolysosomes (arrow; original magniﬁcation 25,000). (g) In rare cells, the autophagolysomes appear to form larger, membrane-bound
aggregates (arrow; original magniﬁcation 6,000), corresponding to the (h) scattered large round eosinophilic inclusions seen in a minority of
cells (arrow; hematoxylin and eosin, original magniﬁcation 600).
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Table 2. Lysozyme-induced nephropathy (LyN): teaching points
 Lysozyme is a small cationic protein produced by monocytes that is freely ﬁltered by
the glomerulus and reabsorbed by proximal tubules.
 Overproduction of lysozyme in patients with chronic monocytic or myelomonocytic
leukemia may lead to nephrotic-range proteinuria (lysozymuria).
 Lysozyme-induced nephropathy is a rare cause of acute kidney injury in patients with
chronic monocytic or myelomonocytic leukemia.
 Lysozyme-induced nephropathy is characterized by acute tubular injury with abundant
cytoplasmic granular inclusions that stain strongly for lysozyme and have an ultra-
structural appearance consistent with that of autophagolysosomes.
D Santoriello et al.: Lysozyme-Induced Nephropathy NEPHROLOGY ROUNDSLysozyme is a small cationic protein (molecular
weight, 15 kDa) that is freely ﬁltered by the glomer-
ulus.8 Lysozyme is reabsorbed in the proximal tubule,
where it is taken up by endocytosis and catabolized in
phagolysosomes.10 Despite the proximal tubules’ high
absorptive capacity for lysozyme,11,12 marked over-
production of lysozyme in patients with monocytic
leukemias may exceed the transport maximum, leading
to nephrotic-range nonalbumin proteinuria, as appears
to have occurred in this case.13,14 By protein electro-
phoresis, lysozyme migrates in the gamma (g) region.
Therefore, the presence of nonalbumin proteinuria
with an increased g-globulin fraction but without
detectable monoclonal bands by immunoﬁxation elec-
trophoresis may be a useful indicator of lysozymuria in
the appropriate clinical context.15 Unfortunately, these
studies were not performed.
In the setting of monocytic and myelomonocytic
leukemias, including chronic and acute forms, a steady
proportion of the ﬁltered load of lysozyme accumulates
in proximal tubular cells, allowing the kidney to act as
a reservoir for circulating lysozyme.12 There appears to
be a threshold above which the concentration of lyso-
zyme, a lytic enzyme with bactericidal properties,7
becomes toxic to proximal tubular cells, leading to
the development of acute tubular injury and AKI.
Indeed, lysozymuria can impair proximal tubular cell
function,16 leading to renal insufﬁciency, hypokalemia
secondary to renal potassium wasting, and low-level
tubular albuminuria, but not Fanconi syndrome.9,17
However, elevated serum and urine lysozyme levels
commonly occur in patients with monocytic and
myelomonocytic leukemias and are usually not associ-
ated with the development of AKI.16,18 Therefore,
kidney biopsy is needed to establish a deﬁnitive
diagnosis of LyN.
Descriptions of the pathologic ﬁndings in LyN are
limited. An early report described tubular degenerative
changes accompanied by hyaline droplets in proximal
tubules, but also described hyaline droplets in patients
with monocytic or myelomonocytic leukemia and
intact renal function.16 A more recent report described
coarse protein granules in proximal tubules by light
microscopy, corresponding with the ultrastructural
ﬁnding of large and prominent but relatively isomor-
phic lysosomes.7 In the case reported herein, the direct
toxicity of lysozyme was associated with the distinc-
tive ultrastructural ﬁnding of abundant autophagoly-
sosomes containing degenerating organellar debris and
strong immunostaining of proximal tubules for lyso-
zyme. Similar ultrastructural ﬁndings have been
described in rats transplanted with chloroleukemia, a
myelomonoblastic tumor that also secretes large
amounts of lysozyme, leading to lysozymuria.19Kidney International Reports (2017) 2, 84–88Other causes of AKI should be excluded in patients
with CMML. Laboratory evaluation of our patient also
revealed hyperuricemia, mild hyperphosphatemia, and
mild hypocalcemia, raising the possibility of concur-
rent tumor lysis syndrome. However, no intratubular
deposition of uric acid crystals or calcium phosphate
salts was seen on kidney biopsy. Nonetheless, elevated
serum uric acid levels may still have contributed to
AKI in our patient, as hyperuricemia may reduce renal
plasma ﬂow and may inhibit proximal tubular cell
proliferation.20 Although unlikely in the case reported
herein, alternative etiologies of lysozymuria should be
considered. Heavy lysozymuria may occur rarely as a
form of overﬂow proteinuria in the setting of other
disease states associated with macrophage activation
and overproduction of lysozyme (including sarcoidosis)
or at very low levels in the setting of tubular pro-
teinuria related to proximal tubular cell dysfunction.7,9
The treatment of CMML is initially supportive;
however, the development of leukemia-associated or-
gan damage may be an indication for more aggressive
treatment, including cytoreductive therapy or use of
hypomethylating agents.21 Variable improvement in
kidney function has been described in patients
receiving CMML-speciﬁc chemotherapy who have
direct leukemic inﬁltration or overproduction of lyso-
zyme by the malignant cells.22 Although our patient
had a good hematologic response to chemotherapy, he
remained dialysis dependent.
CONCLUSION
In conclusion, acute and chronic monocytic and
myelomonocytic neoplasms, most notably CMML, are
associated with overproduction of lysozyme, resulting
in elevated serum and urine levels. Lysozyme is freely
ﬁltered by the glomerulus, and can be associated with
nephrotic-range lysozymuria. Lysozyme accumulates
in proximal tubular cells, and there is a threshold at
which this accumulation is associated with renal
potassium wasting, toxic proximal tubular injury, and
AKI. LyN is a rare and likely underrecognized
etiology of AKI that has a distinctive pathologic
appearance characterized by acute tubular necrosis,
with increased cytoplasmic granules in proximal87
NEPHROLOGY ROUNDS D Santoriello et al.: Lysozyme-Induced Nephropathytubular cells at the light microscopic level, corre-
sponding to abundant phagolysosomes containing
partially digested organellar debris at the ultrastruc-
tural level, with strong proximal tubular cytoplasmic
staining for lysozyme (Table 2). Recognition of this
rare etiology of AKI may guide chemotherapeutic
intervention in the management of acute and chronic
monocytic and myelomonocytic leukemias.
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